Sentence examples for implementation of adjuvant from inspiring English sources

These patients, with optimization of ventilator settings or implementation of adjuvant therapy, rapidly increase their oxygenation within 24 h and have a low mortality.

The recent period differed from the previous one by implementation of adjuvant treatments of septic shock including albumin infusion as fluid volume therapy, low-dose glucocorticoids, and intensive insulin therapy.

11, 12 Despite many concerns raised regarding study design, radiation administration, and quality control of the study, 13– 18 conclusions drawn from the ESPAC-1 trial have raised doubts about the implementation of adjuvant CRT for pancreatic adenocarcinoma in spite of other data showing efficacy of adjuvant or neoadjuvant CRT for other gastrointestinal cancer sites.

Implementation of adjuvant therapy with dex (10 mg IV, given every 6 hours for 4 days started before or with the first dose of parenteral antibiotics) reduced mortality rate and the proportion of patients with unfavorable outcomes in the Netherlands [11].

With the implementation of imatinib for adjuvant treatment in GIST more patients are exposed to imatinib, which may also increase the occurrence of imatinib-induced liver damage.

This is our first question, and its discussion may lead to modifications of the trial process leading to earlier implementation of neoadjuvant and adjuvant clinical trial testing.

The management of rectal cancer (RC) has substantially changed over the last decades with the implementation of neoadjuvant chemoradiotherapy, adjuvant therapy and improved surgery such as total mesorectal excision (TME).

From the clinical point of view a relevant question is how worth could be the adjuvant implementation of catumaxomab.

These biological features together with the implementation of screening and systematic adjuvant treatment programmes suggest that the prognoses of unilateral and bilateral breast cancers in modernising Asian countries are distinct from those observed in Western nations.

If clinical efficacy and safety are observed in studies on advanced-stage cancer patients, clinical development progresses targeting earlier stage patients and the implementation of clinical studies on adjuvant therapy is also possible.

As for patients relapsing say >1 year following termination of adjuvant therapy, re-implementation of the aromatase inhibitor may be a reasonable choice.